Abstract
The Kruppel-like transcription factor KLF6 is a novel tumor-suppressor gene mutated in a significant fraction of human prostate cancer. It is localized to human chromosome 10p14–15, a region that displays frequent loss of heterozygosity in glioblastoma multiforme (GBM). Indeed, mutations of the KLF6 gene have recently been reported in this tumor type. In this study, we report that the expression of KLF6 is attenuated in human GBM when compared with primary astrocytes. Expression of KLF6 in GBM cells reverts their tumorigenicity both in vitro and in vivo, which is correlated with its transactivation of the p21/CIP1/WAF1 promoter. Additionally, KLF6 inhibits cellular transformation induced by several oncogenes (c-sis/PDGF-B, v-src, H-Ras, and EGFR) that are components of signaling cascades implicated in GBM. Our results provide the first evidence of functional tumor suppression by KFL6, and its loss may contribute to glial tumor progression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Banker G and Goslin K . (1998). Culturing Nerve Cells. MIT Press: Cambridge, MA.
Botella LM, Sanchez-Elsner T, Sanz-Rodriguez F, Kojima S, Shimada J, Guerrero-Esteo M, Cooreman MP, Ratziu V, Langa C, Vary CP, Ramirez JR, Friedman S and Bernabeu C . (2002). Blood, 100, 4001–4010.
Broome MA and Hunter T . (1996). J. Biol. Chem., 271, 16798–16806.
Chan AM, Miki T, Meyers KA and Aaronson SA . (1994). Proc. Natl. Acad. Sci. USA, 91, 7558–7562.
Di Fiore PP, Pierce JH, Fleming TP, Hazan R, Ullrich A, King CR, Schlessinger J and Aaronson SA . (1987). Cell, 51, 1063–1070.
Ding H, Roncari L, Shannon P, Wu X, Lau N, Karaskova J, Gutmann DH, Squire A, Nagy A and Guha A . (2001). Cancer Res., 61, 3826–3836.
Givol I, Givol D, Rulong S, Resau J, Tsarfaty I and Hughes SH . (1995). Oncogene, 11, 2609–2618.
Harada K, Nishizaki T, Maekawa K, Kubota H, Harada K, Suzuki M, Ohno T, Sasaki K and Soeda E . (2000). Genomics, 67, 268–272.
Holland EC . (2000). Proc. Natl. Acad. Sci. USA, 97, 6242–6244.
Honda R, Tanaka H and Yasuda H . (1997). FEBS Lett., 420, 25–27.
Jeng YM and Hsu HC . (2003). Int. J. Cancer, 105, 625–629.
Kato H, Kato S, Kumabe T, Sonoda Y, Yoshimoto T, Kato S, Han SY, Suzuki T, Shibata H, Kanamaru R and Ishioka C . (2000). Clin. Cancer Res., 6, 3937–3943.
Kimmelman AC, Ross DA and Liang BC . (1996). Genomics, 34, 250–254.
Kleihues P and Cavenee WK . (2000). World Health Organization. IARC/WHO: Lyon.
Kojima S, Hayashi S, Shimokado K, Suzuki Y, Shimada J, Crippa MP and Friedman SL . (2000). Blood, 15, 1309–1316.
Kon H, Sonoda Y, Kumabe T, Yoshimoto T, Sekiya T and Murakami Y . (1998). Oncogene, 16, 257–263.
Kruse CA, Mitchell DH, Kleinschmidt-DeMasters BK, Franklin WA, Morse HG, Spector EB and Lillehei KO . (1992). In Vitro Cell Dev. Biol., 28A, 609–614.
LaRochelle WJ, Giese N, May-Siroff M, Robbins KC and Aaronson SA . (1990). Science, 248, 1541–1544.
Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK and DePinho RA . (2001). Genes Dev., 15, 1311–1333.
Narla G, Heath KE, Reeves HL, Li D, Giono LE, Kimmelman AC, Gluckman MJ, Narla J, Eng FJ, Chan AM, Ferrari AC, Martignetti JA and Friedman SL . (2001). Science, 294, 2563–2566.
Osada M, Tolkacheva T, Li W, Chan TO, Tsichlis PN, Saez R, Kimmelman AC and Chan AM . (1999). Mol. Cell. Biol., 19, 6333–6344.
Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon-Cardo C, Catoretti G, Fisher PE and Parsons R . (1999). Proc. Natl. Acad. Sci. USA, 16, 1563–1568.
Radany EH, Brenner M, Besnard F, Bigornia V, Bishop JM and Deschepper CF . (1992). Proc. Natl. Acad. Sci. USA, 15, 6467–6471.
Ratziu V, Lalazar A, Wong L, Dang Q, Collins C, Shaulian E, Jensen S and Friedman SL . (1998). Proc. Natl. Acad. Sci. USA, 95, 9500–9505.
Satoh T, Endo M, Nakafuku M, Akiyama T, Yamamoto T and Kaziro Y . (1990). Proc. Natl. Acad. Sci. USA, 87, 7926–7929.
Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, Cordon-Cardo C and Lowe SW . (2001). Nature (London), 409, 207–211.
Theurillat JP, Hainfellner J, Maddalena A, Weissenberger J and Aguzzi A . (1999). Am. J. Pathol., 154, 581–590.
Turner J and Crossley M . (1999). Trends Biochem. Sci., 24, 236–240.
Voesten AM, Bijleveld EH, Westerveld A and Hulsebos TJ . (1997). Genes Chromosomes Cancer, 20, 167–172.
Zhang W, Geiman DE, Shields JM, Dang DT, Mahatan CS, Kaestner KH, Biggs JR, Kraft AS and Yang VW . (2000). J. Biol. Chem., 16, 18391–18398.
Acknowledgements
This work was supported by NIH Grants CA78509 (AMC), and DK37340, DOD PC020770 (SLF). ACK was supported by an NCI predoctoral training Grant (CA78207). AMC is a recipient of a Career Scientist Award from the Irma T Hirschl Foundation. SB and GN were supported by Howard Hughes Medical Institute Medical Student Research Fellowships.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kimmelman, A., Qiao, R., Narla, G. et al. Suppression of glioblastoma tumorigenicity by the Kruppel-like transcription factor KLF6. Oncogene 23, 5077–5083 (2004). https://doi.org/10.1038/sj.onc.1207662
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207662
Keywords
This article is cited by
-
Galectin-1 is a poor prognostic factor in patients with glioblastoma multiforme after radiotherapy
BMC Cancer (2018)
-
KLF6 and STAT3 co-occupy regulatory DNA and functionally synergize to promote axon growth in CNS neurons
Scientific Reports (2018)
-
KLF6 depletion promotes NF-κB signaling in glioblastoma
Oncogene (2017)
-
Krüpple-like factors in the central nervous system: novel mediators in Stroke
Metabolic Brain Disease (2015)
-
Krüppel-like factors in cancer
Nature Reviews Cancer (2013)